- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.02. | Comera Life Sciences Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.02. | NSE - Comera Life Sciences Holdings, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 13.02. | Delisting of Securities of Sono Group N.V.; Baudax Bio, Inc.; Comera Life Sciences Holdings, Inc.; Missfresh Limited; Rose Hill Acquisition Corporation; Axcella Health; Zivo Bioscience, Inc.; Sonic Foundry, Inc.; Mobiquity Technologies, Inc. and others | 325 | GlobeNewswire (Europe) | NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common shares of Sono Group N.V. Sono Group N.V.'s securities were suspended on July 21, 2023... ► Artikel lesen | |
| 30.01. | Comera Life Sciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.01. | Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option | 3 | GlobeNewswire (USA) | ||
| 29.12.23 | Comera Life Sciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.12.23 | Comera Life Sciences to explore strategic alternatives | 1 | Seeking Alpha | ||
| 06.12.23 | Comera Life Sciences Announces Process Exploring Strategic Alternatives | 189 | GlobeNewswire (Europe) | WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines... ► Artikel lesen | |
| 06.12.23 | Comera Life Sciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.11.23 | Comera Life Sciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.11.23 | Comera Life Sciences Appoints Dorothy Clarke to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 09.11.23 | Comera Life Sciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.11.23 | Comera Life Sciences Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.11.23 | Comera Life Sciences GAAP EPS of -$0.10, revenue of $0.14M | 1 | Seeking Alpha | ||
| 09.11.23 | Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights | 108 | GlobeNewswire (Europe) | - Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company - - Expanded and strengthened Comera's global patent portfolio... ► Artikel lesen | |
| 10.08.23 | Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights | 267 | GlobeNewswire (Europe) | - Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company - - Received notice that Nasdaq granted Comera's request for... ► Artikel lesen | |
| 11.05.23 | Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights | 526 | GlobeNewswire (Europe) | - Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company - - Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab)... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,610 | -1,53 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,990 | -0,60 % | Bayer auf dem Weg aus der Krise. Stehen auch Defence Therapeutics und BioNTech mit ihren Onkologie-Pipelines vor dem Turnaround? | Nach mehreren Jahren, in denen der Pharma- und Agrarchemiekonzern Bayer von einer Krise in die nächste stolperte, zeichnen sich nun Zeichen einer Erholung am Horizont ab. Während Bayer seinen langen... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,988 | 0,00 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,780 | 0,00 % | Beam Therapeutics GAAP EPS of -$1.21 beats by $0.23, revenue of $7.41M misses by $7.25M | ||
| RECURSION PHARMACEUTICALS | 8,940 | 0,00 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
| ONCOLYTICS BIOTECH | 1,090 | -0,91 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| ASSERTIO | 1,220 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports First Quarter 2024 Financial Results | First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to $80.7 Million... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,320 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 10,390 | 0,00 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,015 | 0,00 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 10,225 | 0,00 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,420 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,450 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,710 | 0,00 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 12,260 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
COMERA LIFE SCIENCES HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,223 Euro und damit -0,04 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
